NHS England Clinical Advisory Group.
Chiesi UK and Ireland supports NHS workforce to address COPD diagnosis backlog
An estimated two million people in the UK are living with undiagnosed chronic obstructive pulmonary disease
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
Number of women in England receiving HRT on the NHS more than doubles
A record two million women were prescribed hormone replacement therapy in 2025/26 compared to 0.8 million in 2020/21
Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands
Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing...
Incyte Biosciences UK announces NICE approval for Opzelura for vitiligo
This is the first approved treatment option in the UK for patients with non-segmental vitiligo
UK and US agree on landmark pharma pricing tariff deal
US tariffs on UK-produced pharmaceuticals will remain at zero for three years
ViiV Healthcare receives NICE recommendation for HIV prevention therapy
The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales
New National Commission launched to strengthen AI regulation
The Commission will unite healthcare leaders, regulators and technology experts to shape future AI governance
NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine
More than 11,000 people are diagnosed with head and neck cancers every year in England
NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS
Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK
UK government publishes 10 Year Health Plan for England to ‘reinvent’ NHS
The plan’s three overarching themes are hospital to community, analogue to digital and sickness to prevention
Novartis shares positive late-stage results for Fabhalta in rare blood disorder PNH
Paroxysmal nocturnal haemoglobinuria affects approximately ten to 20 people per million worldwide